Our results indicate that RPS3 may act as a tumour resistance promoter downstream of SIAH1 by promoting NF-κB-induced transcriptional activation, which is considered to contribute to EOC chemotherapy resistance. This evidence concerns the gene RPS3 and neoplasm.